tetano
Editor, Senior Moderator
Nature
. 2020 Jul 29.
doi: 10.1038/s41586-020-2598-9. Online ahead of print.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Julian Braun[SUP] 1 2 [/SUP], Lucie Loyal[SUP] 1 2 [/SUP], Marco Frentsch[SUP] 3 [/SUP], Daniel Wendisch[SUP] 4 [/SUP], Philipp Georg[SUP] 4 [/SUP], Florian Kurth[SUP] 4 5 [/SUP], Stefan Hippenstiel[SUP] 4 [/SUP], Manuela Dingeldey[SUP] 1 2 [/SUP], Beate Kruse[SUP] 1 2 [/SUP], Florent Fauchere[SUP] 1 2 [/SUP], Emre Baysal[SUP] 1 2 [/SUP], Maike Mangold[SUP] 1 2 [/SUP], Larissa Henze[SUP] 1 2 [/SUP], Roland Lauster[SUP] 1 6 [/SUP], Marcus A Mall[SUP] 7 8 [/SUP], Kirsten Beyer[SUP] 7 [/SUP], Jobst R?hmel[SUP] 7 [/SUP], Sebastian Voigt[SUP] 9 [/SUP], J?rgen Schmitz[SUP] 10 [/SUP], Stefan Miltenyi[SUP] 10 [/SUP], Ilja Demuth[SUP] 11 [/SUP], Marcel A M?ller[SUP] 12 [/SUP], Andreas Hocke[SUP] 4 [/SUP], Martin Witzenrath[SUP] 4 [/SUP], Norbert Suttorp[SUP] 4 [/SUP], Florian Kern[SUP] 13 8 [/SUP], Ulf Reimer[SUP] 13 [/SUP], Holger Wenschuh[SUP] 13 [/SUP], Christian Drosten[SUP] 12 14 [/SUP], Victor M Corman[SUP] 12 [/SUP], Claudia Giesecke-Thiel[SUP] 15 [/SUP], Leif Erik Sander[SUP] 16 [/SUP], Andreas Thiel[SUP] 17 18 [/SUP]
Affiliations
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic[SUP]1,2[/SUP]. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms determining such variable outcomes remain unresolved. Here, we investigated SARS-CoV-2 spike glycoprotein (S)-reactive CD4[SUP]+[/SUP] T cells in peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors (HD). We detected SARS-CoV-2 S-reactive CD4[SUP]+[/SUP] T cells in 83% of patients with COVID-19 but also in 35% of HD. S-reactive CD4[SUP]+[/SUP] T cells in HD reacted primarily to C-terminal S epitopes, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared to N-terminal epitopes. S-reactive T cell lines generated from SARS-CoV-2-naive HD responded similarly to C-terminal S of human endemic coronaviruses 229E and OC43 and SARS-CoV-2, demonstrating the presence of S-cross-reactive T cells, probably generated during past encounters with endemic coronaviruses. The role of pre-existing SARS-CoV-2 cross-reactive T cells for clinical outcomes remains to be determined in larger cohorts. However, the presence of S-cross-reactive T cells in a sizable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming COVID-19 vaccine trials.
. 2020 Jul 29.
doi: 10.1038/s41586-020-2598-9. Online ahead of print.
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19
Julian Braun[SUP] 1 2 [/SUP], Lucie Loyal[SUP] 1 2 [/SUP], Marco Frentsch[SUP] 3 [/SUP], Daniel Wendisch[SUP] 4 [/SUP], Philipp Georg[SUP] 4 [/SUP], Florian Kurth[SUP] 4 5 [/SUP], Stefan Hippenstiel[SUP] 4 [/SUP], Manuela Dingeldey[SUP] 1 2 [/SUP], Beate Kruse[SUP] 1 2 [/SUP], Florent Fauchere[SUP] 1 2 [/SUP], Emre Baysal[SUP] 1 2 [/SUP], Maike Mangold[SUP] 1 2 [/SUP], Larissa Henze[SUP] 1 2 [/SUP], Roland Lauster[SUP] 1 6 [/SUP], Marcus A Mall[SUP] 7 8 [/SUP], Kirsten Beyer[SUP] 7 [/SUP], Jobst R?hmel[SUP] 7 [/SUP], Sebastian Voigt[SUP] 9 [/SUP], J?rgen Schmitz[SUP] 10 [/SUP], Stefan Miltenyi[SUP] 10 [/SUP], Ilja Demuth[SUP] 11 [/SUP], Marcel A M?ller[SUP] 12 [/SUP], Andreas Hocke[SUP] 4 [/SUP], Martin Witzenrath[SUP] 4 [/SUP], Norbert Suttorp[SUP] 4 [/SUP], Florian Kern[SUP] 13 8 [/SUP], Ulf Reimer[SUP] 13 [/SUP], Holger Wenschuh[SUP] 13 [/SUP], Christian Drosten[SUP] 12 14 [/SUP], Victor M Corman[SUP] 12 [/SUP], Claudia Giesecke-Thiel[SUP] 15 [/SUP], Leif Erik Sander[SUP] 16 [/SUP], Andreas Thiel[SUP] 17 18 [/SUP]
Affiliations
- PMID: 32726801
- DOI: 10.1038/s41586-020-2598-9
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused the rapidly unfolding coronavirus disease 2019 (COVID-19) pandemic[SUP]1,2[/SUP]. Clinical manifestations of COVID-19 vary, ranging from asymptomatic infection to respiratory failure. The mechanisms determining such variable outcomes remain unresolved. Here, we investigated SARS-CoV-2 spike glycoprotein (S)-reactive CD4[SUP]+[/SUP] T cells in peripheral blood of patients with COVID-19 and SARS-CoV-2-unexposed healthy donors (HD). We detected SARS-CoV-2 S-reactive CD4[SUP]+[/SUP] T cells in 83% of patients with COVID-19 but also in 35% of HD. S-reactive CD4[SUP]+[/SUP] T cells in HD reacted primarily to C-terminal S epitopes, which show a higher homology to spike glycoproteins of human endemic coronaviruses, compared to N-terminal epitopes. S-reactive T cell lines generated from SARS-CoV-2-naive HD responded similarly to C-terminal S of human endemic coronaviruses 229E and OC43 and SARS-CoV-2, demonstrating the presence of S-cross-reactive T cells, probably generated during past encounters with endemic coronaviruses. The role of pre-existing SARS-CoV-2 cross-reactive T cells for clinical outcomes remains to be determined in larger cohorts. However, the presence of S-cross-reactive T cells in a sizable fraction of the general population may affect the dynamics of the current pandemic, and has important implications for the design and analysis of upcoming COVID-19 vaccine trials.